Search Results

You are looking at 91 - 100 of 305 items for :

  • "targeted agents" x
  • Refine by Access: All x
Clear All
Full access

NCCN News

targeted agents in NSCLC. Afatinib is FDA approved under the brand name Gilotrif for the first-line treatment of patients with metastatic NSCLC whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution

Full access

Lymphoma 101: The Plot Thickens

Presented by: Leo I. Gordon

RECIL criteria clarified response assessment in patients receiving novel immune therapy and targeted agents that generate unique imaging situations. “These criteria still have to be worked out and haven’t been used quite as much in clinical trials as the

Full access

Relapsed/Refractory CLL/SLL: Overcoming Resistance to Covalent BTKi and/or BCL2 Inhibitors

Presented by: Brian T. Hill

pirtobrutinib in this patient population “robust.” In summary, the treatment of CLL with targeted agents as initial therapy results in tremendous outcomes for most patients with prolonged disease control. In contrast to the prior era, we anticipate seeing more

Full access

Prostate Cancer, Version 1.2014

James L. Mohler, Philip W. Kantoff, Andrew J. Armstrong, Robert R. Bahnson, Michael Cohen, Anthony Victor D’Amico, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Mark H. Kawachi, Michael Kuettel, Richard J. Lee, Gary R. MacVicar, Arnold W. Malcolm, David Miller, Elizabeth R. Plimack, Julio M. Pow-Sang, Sylvia Richey, Mack Roach III, Eric Rohren, Stan Rosenfeld, Eric J. Small, Sandy Srinivas, Cy Stein, Seth A. Strope, Jonathan Tward, Patrick C. Walsh, Dorothy A. Shead, and Maria Ho

. Most patients with castration-recurrent or -resistant prostate cancer (CRPC) die of bone metastases and related complications. The recently approved radium-223 is the first bone-targeting agent to demonstrate a survival benefit in these patients

Full access

Impact of the 7th Edition AJCC Staging Classification on the NCCN Clinical Practice Guidelines in Oncology for Gastric and Esophageal Cancers

Vivian E. Strong, Thomas A. D’Amico, Lawrence Kleinberg, and Jaffer Ajani

esophageal staging. These histologies were originally grouped together because the prognosis seemed similar, but with the introduction of novel chemotherapy agents and targeted agents, treatment strategies by stage will likely diverge. For example, when

Full access

Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary

Jennifer Shih, Babar Bashir, Karen S. Gustafson, Mark Andrake, Roland L. Dunbrack, Lori J. Goldstein, and Yanis Boumber

-trastuzumab emtansine and lapatinib have been approved (NCCN Guidelines for Breast Cancer). 1 Given the central role of targeted agents in the management of patients with tumors harboring these types of changes, testing for genomic alterations is recommended as part of

Full access

Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer

Rishi Agarwal, Jiang Wang, Keith Wilson, William Barrett, and John C. Morris

critical pathways in tumorigenesis have identified potentially targetable molecular mutations in a number of cancers. As a result, a number of studied targeted agents have demonstrated antitumor activity in preclinical models of thyroid cancer. 5 – 7

Full access

Novel and Emerging Treatment Strategies for Acute Myeloid Leukemia

Presented by: Eunice S. Wang

chemoresistance, Dr. Wang noted. Numerous oral tyrosine kinase inhibitors against FLT3 (also known as FLT3-TKIs) are in development. The first-generation FLT3-TKIs (lestaurtinib, midostaurin, sorafenib) are multikinase targeted agents that were repurposed as

Full access

Treatment of Stage IV Colon Cancer in the United States: A Patterns-of-Care Analysis

Xiang Gao, Amanda R. Kahl, Paolo Goffredo, Albert Y. Lin, Praveen Vikas, Imran Hassan, and Mary E. Charlton

Background De novo stage IV colon cancer accounts for approximately 22% of new cases of colon cancer and has an overall 5-year survival of approximately 14%. 1 The development of novel targeted agents and their use in combination with chemotherapy

Full access

New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma

Christopher A. Barker and April K. Salama

Advanced Disease With the approval of PD-1 checkpoint inhibitors and targeted agents for first-line treatment of advanced/metastatic disease, the direction for second-line therapy is less certain because most of the data for these agents come from studies